DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bsgwxk/monoclonal) has announced the addition of the "Monoclonal Antibodies Partnering Terms and Agreements" report to their offering.
The report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest monoclonal antibody deals announced in the healthcare sectors.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since 2009 including financial terms where available including over 700 links to online deal records of actual biomarker partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in monoclonal antibody dealmaking
Chapter 3 - Leading monoclonal antibody deals
Chapter 4 - Big pharma monoclonal antibody deals
Chapter 5 - Big biotech monoclonal antibodies deals
Chapter 6 - Monoclonal antibody dealmaking directory
Chapter 7 - Monoclonal antibody deals by individual technology type
For more information visit http://www.researchandmarkets.com/research/bsgwxk/monoclonal